Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding director share awards and does not contain financial performance data.
Material Changes
On September 30, 2006, Non-Executive Directors were provisionally allocated awards of Ordinary Shares and American Depository Shares (ADSs) for the service period of July 1, 2006, to September 30, 2006. The specific allocations are as follows:
- Sir Christopher Gent: 1,755.62 Ordinary Shares
- Mr Lawrence Culp: 678.66 ADSs
- Sir Crispin Davis: 1,053.37 Ordinary Shares
- Sir Deryck Maughan: 678.66 ADSs
- Dr Daniel Podolsky: 254.50 Ordinary Shares
- Sir Ian Prosser: 790.03 ADSs
- Dr Ronaldo Schmitz: 632.02 Ordinary Shares
- Mr Tom de Swaan: 263.34 ADSs
- Sir Robert Wilson: 351.12 Ordinary Shares
The Company and directors were informed of these allocations on October 2, 2006.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of director share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of shares and ADSs allocated to Non-Executive Directors for the Q3 2006 service period.
- Confirm the provisional nature of the allocations as of September 30, 2006.
- Review the specific breakdown between Ordinary Shares and ADSs for each director listed.